3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
19
Neoplasm Metastasis
3
Neoplasms
2
Bulbo-Spinal Atrophy, X-Linked
2
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Advanced Solid Tumor
1
Adenocarcinoma
1
Interventions
Oxaliplatin
9
Capecitabine
9
Fluorouracil
7
pembrolizumab
6
Paclitaxel
6
Leucovorin
6
Cisplatin
5
zolbetuximab
4
trastuzumab deruxtecan
3
enzalutamide
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Gemcitabine
3
Docetaxel
3
fludarabine
2
darolutamide
2
Taxes
2
Ramucirumab
2
Radiotherapy, Image-Guided
2
Radiosurgery
2
Pemetrexed
2
Nivolumab
2
Irinotecan
2
Cyclophosphamide
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
abiraterone
×
90 days
×
Clear all
NCT06592924
2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3
Recruiting
830 enrolled